
Pierre Fabre Laboratories collaborate with Vernalis
The French biotech company combines its experience in innovation, development, manufacturing, and commercialisation in oncology with the expertise of...

Amyl Therapeutics bags €11m Series A extension
Amyl Therapeutics SA has secured €5m Series A extension from long-term investors Merieux Equity Partners and Noshaq, together with Mr Evren Ucok as a...

CPHI: Trends shaping pharma's path
Despite challenges such as funding slowdowns for biotechs and concerns about high inflation, the industry remains cautiously optimistic,...

Abingworth raises $356m for new CCD fund
London-headquartered institutional investor Abingworth has closed its new Clinical Co-Development Co-Investment Fund at $356m, exceeding its target...

Breakthrough in COPD treatment
Sanofi's duplimab (Dupixent®) showcased notable efficacy in reducing exacerbations and enhancing lung function in its second positive Phase III...

Repairing MS-caused damage with stem cells
Results of a investigator-initiated Phase I stem cell therapy trial have shown promise as a treatment for progressive multiple sclerosis. The...

Memo Therapeutics AG raises CHF25m
The CHF25m Series C round of Schlieren-based Memo Therapeutics AG was led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital,...